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The purpose of this article is to review the imaging techniques that have changed and are anticipated to change
bladder cancer evaluation. The use of multidetector 64-slice computed tomography (CT) and magnetic resonance
imaging (MRI) remain standard staging modalities. The development of functional imaging such as dynamic
contrast-enhanced MRI, diffusion-weighted MRI and positron emission tomography (PET)-CT allows characterization
of tumor physiology and potential genotypic activity, to help stratify and inform future patient management. They
open up the possibility of tumor mapping and individualized treatment solutions, permitting early identification of
response and allowing timely change in treatment. Further validation of these methods is required however, and at
present they are used in conjunction with, rather than as an alternative to, conventional imaging techniques.
Keywords: Bladder cancer, Diffusion-weighted MRI, Multidetector computed tomography, PET-CT, Staging,
Ultrasound, Virtual cystoscopyIntroduction
Bladder cancer is a common disease with significant
associated morbidity and mortality. Globally it is the
ninth most common cause of cancer related death in men
[1,2]. The clinical spectrum at presentation can be divided
in to those with (i) superficial or non-muscle-invasive
bladder cancer (NMIBC), approximately 70% to 80% of
patients; (ii) muscle-invasive bladder cancer (MIBC),
approximately 20% at presentation; and (iii) metastatic
disease [3].The challenge
Anatomically the bladder is divided into several layers.
Accurate local staging with imaging is dependent on
reliably distinguishing these layers. Clinical staging of
the primary tumor is with bimanual examination under
anesthesia. In those with MIBC this has been shown to
be inaccurate in 23% to 50% of cases [4,5]. Transurethral
resection of bladder tumor (TURBT) also understages
tumors; approximately 30% to 50% patients are
understaged at the time of cystectomy [6-10]. Therefore,
accurate radiological correlation is important to help
guide patient management.
The objective of any staging modality is to achieve
adequate visualization of the primary tumor, extent of* Correspondence: Robert.huddart@rmh.nhs.uk
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distribution, and reproduction in any mediumloco regional disease and to determine the presence of
metastases. However, conventional imaging modalities
are unable to identify microscopic disease and can be
inaccurate in identifying macroscopic disease. To address
this newer imaging techniques are being explored to
improve pretreatment staging, predict early response to
treatment and provide non-invasive alternatives to
cystoscopy for those requiring long-term surveillance.
This article will review the development of imaging
techniques that have changed, and are anticipated to
change, bladder cancer evaluation.Computed tomography (CT)
Multidetector (64-slice) CT scanning has provided the
mainstay in radiological assessment. It has a reported
sensitivity of 85% and specificity of 94% for the diagnosis
of bladder cancers [11]. Detection is dependent on the
morphology and size of the tumor. Flat lesions, carcinoma
in situ (CIS), tumors less than 1 cm and in those whom
recent resection has been performed, are more likely to be
falsely negative [5,11,12]. Previous biopsy, inflammation,
systemic chemotherapy and intravesical drugs also
interfere with interpretation [5,13].
CT remains the modality of choice for investigating
hematuria and has replaced intravenous urogram (IVU)
at most centers; its precise role in diagnosing bladder
cancer is controversial. Although a 64-slice multidetector
CT provides high spatial resolution allowing visualizationCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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extent of locoregional disease [14]. It is limited by
interobserver variability and inability to distinguish the
muscle layers of the bladder [5,15].Ultrasound (US)
US is at present not used routinely in clinical practice
for the assessment of known bladder cancer, although
the presence of hydronephrosis is suggestive of MIBC. It is
however an important diagnostic tool in the investigation
of hematuria in particular to assess large renal masses/
upper renal tracts. Bladder tumors may be visualized by
ultrasound but a negative test does not exclude the
presence of bladder cancer.
Two-dimensional transabdominal and transvaginal
US have been investigated with regards to aiding
bladder cancer staging but transurethral ultrasound has
demonstrated the best ability to visualize depth of tumor
penetration through the bladder wall [16,17]. Use of
two-dimensional US is often limited by the subjectivity
and expertise of the examiner. It is also unreliable in
determining deeply infiltrating disease and nodal
involvement [5]. Contrast-enhanced US (CE US) has been
shown to be superior to conventional US in differentiating
non-invasive and invasive bladder tumors [18,19]. Prior to
TURBT CE US has a reported accuracy of 88.4% versus
72.1% compared to standard two-dimensional US, with
94.7% sensitivity for tumors greater than 5 mm; for
lesions less than 5 mm sensitivity is reduced to 20% with
a negative predictive value of 28.6% [18].
Three-dimensional US has been developed to provide
reconstruction of the actual tumor with visualization of
the bladder wall layers. The volume data can be
retrieved and manipulated as if in real time, which
increases objectivity, allows views in multiple planes to be
obtained and improves the rate of primary bladder tumor
diagnosis (88.9% with two-dimensional US versus 100%
with three-dimensional US) when identifying T3b disease
[20]. The disadvantage of this technique is that the entire
tumor is not visualized and detection is particularly
difficult when flat, plaque like tumors are present, there is
coexistent calcification, the abdominal wall is rigid or the
patient has central obesity [21].
Three-dimensional CE US uses enhanced images in
three orthogonal planes and reflections of microbubbles
to depict blood vessels. This has been shown to be
clinically useful in differentiating MIBC and NMIBC
[21]. Three-dimensional CE US may also have future
role in assessing treatment response of the primary
tumor to guide bladder-sparing approaches. Its use in
assessing treatment has been evaluated other solid
tumors including primary liver cancer following local
therapy [22].Although recent developments in US techniques
overcome many of the limitations of two-dimensional
US, they remain under investigation and have yet not
translated in to widespread clinical use.
Magnetic resonance imaging (MRI)
MRI has excellent soft tissue resolution and multiplanar
capabilities, which has made it an important staging
modality for bladder cancer. Fundamental to its import-
ance in local staging is the ability to manipulate image
contrast by using different sequences. On T2-weighted
images the bladder tumor is usually more conspicuous.
The signal from perivesical fat can be suppressed using
short tau inversion recovery (STIR) sequences, allowing
signal from the tumor to be highlighted by suppressing
signal from adjacent surrounding normal tissue [5,23,24].
In conjunction with gadolinium-containing contrast
(Gd-Ca), MRI has an accuracy of 85% in differentiating
NMIBC from MIBC and 82% accuracy in distinguishing
organ confined disease from non-organ confined disease
[25]. However, Gd-Ca should be avoided in those with
renal impairment (estimated glomerular filtration rate
(GFR) <60 ml/minute), as there is an increased risk of
developing nephrogenic systemic fibrosis [26].
The clearest advantage of MRI over CT is the ability
to determine the presence of muscle-invasive and
extravesicle disease, and is our preferred modality of
local staging prior to definitive radical treatment in
MIBC.
The use of functional MRI imaging to provide biological
information of tumor characteristics is under investigation.
Dynamic contrast-enhanced MRI (DCE-MRI) enables
in vivo assessment of tumor blood flow and permeability
using paramagnetic contrast agents. Visualization of
tumor blood flow can be used to identify areas of hypoxia
and subsequently be used to predict treatment response
[27]. It is an effective biomarker in predicting pathological
complete response in those receiving primary chemotherapy
for breast cancer and chemoradiotherapy for rectal
cancer [23,28].
Intrinsic-susceptibility-weighted or blood-oxygenation-
level-dependent (BOLD) MRI, exploits the difference in
magnetic susceptibility of oxyhemoglobin and deoxy
hemoglobin. Deoxyhemoglobin is a paramagnetic molecule
that allows it to act as an intrinsic contrast agent. BOLD
MRI image acquisition during high oxygen concentration
inhalation (carbogen, 95% oxygen, 5% carbon dioxide)
reflects improved tumor oxygenation and blood flow and
may help identify patients more likely to benefit from
carbogen radiosensitization [29].
Diffusion-weighted MRI (DW MRI) is a functional
imaging technique dependent on the inhibitory effect of
cell membranes to the random motion of water molecules
(Brownian motion) to generate image contrast by applying
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gradients, characterized by their b-values. As tumors have
greater cellularity than normal tissue they demonstrate
higher signal intensity (that is, restricted diffusion on MRI,
reflected in the low mean apparent diffusion coefficient
value (ADC)). This has the potential to provide both
qualitative and quantitative information to aid tumor
assessment. Histogram analysis of ADC through the entire
tumor volume captures the diffusivity microenvironment
and may aid identification of the heterogeneity known
to exist within tumors that may have prognostic and
predictive value [30-34].
DW MRI is also more accurate than T2-weighted MRI
in staging both organ confined (≤pT2) (69.7% versus
15.1%) and higher stage tumors (92.5% versus 80.1%), with
a reported sensitivity of 98.1% and positive predictive
value of 100% [35]. There is also evidence that the ADC
value may help identify high-grade tumors, with low ADC
(<1 × 10-3 mm2/s) suggesting G3 disease [36].
Following treatment the ADC value increases, reflecting
decreased cellularity, consistent with response. In other
tumor types change in ADC has been used to identify and
quantify early treatment response that may occur before
conventional assessment of response is seen (for example,
the Response Evaluation Criteria In Solid Tumors
(RECIST) criteria), or where evaluation of morphological
change is difficult to interpret [34,37-39]. DW MRI
therefore has the potential for monitoring treatment
response to chemotherapy or radiotherapy with identifi-
cation of early non-responders who may benefit from
change in treatment approach.
Conventional assessment of local response is with
cystoscopy. One study has explored the role of DW MRI
to assess response to chemoradiotherapy in 23 patients
with MIBC. It demonstrated that the ADC was the only
significant, independent predictor of chemoradiotherapy
response with a sensitivity, specificity and accuracy of
92%, 90% and 91% respectively. Consistent with other
studies higher ADC was associated with unfavorable
response [40].
Preliminary results for lymph node evaluation using
DW MRI do not appear to be accurate (sensitivity
76.4%, specificity 89.4%, positive predictive value 86.6%
and negative predictive value 71.4%) [41].
The clinical use of functional MRI in bladder cancer
assessment is not yet clearly defined but work to date
suggests it likely to provide important information that
may help guide treatment selection.
Nanoparticle-enhanced MRI
Involved lymph node detection by convention is
governed by size and shape. Nodes greater than 1 cm
are considered malignant on CT with a sensitivity of
85%, specificity of 67%, with a false negative rate of 21%[5,14]. However, enlarged reactive, non-malignant lymph
nodes can mimic metastatic involvement with these
modalities. Techniques that evaluate nodal function
rather than morphology are aimed to more accurately
characterize nodal disease.
Lymphotropic nanoparticle enhanced MRI exploits
nodal macrophage function to detect metastases using
ultra-small super-paramagnetic particles of iron oxide
(USPIO) (ferumoxtran-10, SineremW). After intravenous
administration, the USPIO particles reach the lymph
nodes via the lymphatics. Benign nodes have functioning
macrophages, which phagocytose the USPIO causing
them to accumulate within the node. This causes a drop
in signal intensity on T2-weighted images. Metastatic
lymph nodes that are partially or completely infiltrated
are unable to take up these particles effectively.
These nodal regions retain their signal intensity on
T2-weighted images allowing detection on post-contrast
imaging [42,43].
Nodal enhancement is dependent on the tumor burden.
Failure to detect microscopic foci of metastatic disease in
very small lymph nodes leads to false negative results.
False positives are due to reactive hyperplasia, localized
nodal lipomatosis and insufficient USPIO [24]. Despite
these limitations, the reported accuracy when evaluated
prospectively in 58 patients prior to surgery is 95%, with
sensitivity of 96%, specificity of 95%, positive predictive
value of 89% and a negative predictive value of 98% [44].
However, USPIO are no longer readily available, which
limits the scope for further investigation and clinical
application.
Virtual cystoscopy (VC)
Three-dimensional surface modeling is possible using
cross sectional data obtained from CT or MRI, allowing
indirect visualization of the mucosa and simulation of
endoscopic evaluation. This method has been used to
assess a number of other hollow organs including the
colon and bronchus. Once source images are obtained,
VC is performed on a dedicated workstation using a
variety of computer algorithms [45-48].
Previous VC studies have focused on the potential
diagnostic capability of evaluating hematuria. In a
meta-analysis of 3084 patients from 26 studies to deter-
mine the validity of VC by CT, MRI or US, the pooled
sensitivity for bladder cancer detection using CT virtual
cystoscopy, magnetic resonance virtual cystoscopy and US
was 93.9%, 90.8% and 77.9% respectively. The pooled
specificity for bladder cancer detection was 98.1%, 94.8%
and 96.2% respectively [49].
The advantage of this technique is that it is non-
invasive, making it a potential alternative for those
unable to tolerate conventional cystoscopy. It also
allows visualization of areas that are difficult to access
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diverticulae. The disadvantages include inability to ob-
tain pathology and low sensitivity in identifying
smaller tumors (<1 cm), flat lesions and CIS [24,46].
Although VC is unlikely at present to replace conventional
cystoscopy it may be considered in conjunction allowing
the possibility of minimally invasive follow-up. Figure 1
illustrates appearance of tumor as seen on VC and on
CT and MRI.Figure 1 Patient with known T2 N0 M0 bladder cancer (left bladder w
T2-weighted image performed on a 3 T magnetic resonance imaging (MRI
axial diffusion-weighted (DW) MRI at b-value 0, (e) axial DW MRI at b-value
virtual cystoscopy (MRVC) of same tumor with three-dimensional reconstruPositron emission tomography (PET)
PET/CT: metabolic tracers
Composite PET/CT images provide three-dimensional
whole body structural and functional information. The
patient first moves through a spiral CT then a gamma
camera in a single investigation. Radiotracers are used to
identify the altered metabolic activity occurring within
tumors. Metabolic change detectable by PET may precede
anatomical changes on CT or MRI leading to greaterall): (a) contrast-enhanced computed tomography (CT) scan, (b) axial
) unit showing a hypointense lesion, (c) corresponding T1 image, (d)
100, (f) axial DW MRI at b-value 750, and (g) magnetic resonance
ction of tumor bed showing opening into adjacent diverticulum.
Table 1 A summary of imaging modalities and their
current clinical role(s) in staging known muscle-invasive
bladder cancer
Technique Description
CT Mainstay of assessment in locally advanced
and metastatic disease. Limitations are in
assessing primary tumor.
US Two-dimensional techniques have no role
in routine assessment of primary tumor,
however presence of hydronephrosis is
suggestive of MIBC. Contrast-enhanced
and three-dimensional techniques are
under investigation.
MRI Useful in identifying muscle-invasive and
extravesical disease. Functional MRI
currently under investigation as a predictive
tumor biomarker.
Virtual cystoscopy Both CT and MRI data can be used to
reconstruct bladder mucosa and simulate
endoscopic evaluation. Unlike for other
tumor sites such as GI, it is not used
routinely.
PET-CT FDG-PET-CT not used as initial staging
modality. Often used in conjunction with
other imaging if uncertainly exists. FDG
use for staging local disease limited
predominantly by urinary excretion.
Alternative isotopes and receptor specific
molecules are under investigation.
CT, computed tomography; FDG, flurodeoxyglucose; GI, gastrointestinal; MIBC,
muscle-invasive bladder cancer; MRI, magnetic resonance imaging; PET,
positron emission tomography; US, ultrasound.
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alone. This uptake is quantified using the standardized
uptake value (SUV). Uniform radiotracer distribution
throughout the body produces a SUV of 1 [24].
18 F-Flurodeoxyglucose (18-FDG) is currently the most
commonly used PET tracer in oncological imaging and
has an established role in the initial staging, response
assessment and recurrence detection of many cancer
types [50-53]. Its use is dependent on the increase
glucose metabolism occurring within the tumor. However,
it cannot distinguish between increased metabolic rate
occurring as a result of infection, inflammation or the
normal physiological activity in some organs [24].
The use of 18-FDG-PET in staging primary bladder
disease, locally recurrent and perivesical nodal disease
has been difficult because the interference caused by the
urinary excretion of the isotope. A number of techniques
encouraging adequate washout of 18-FDG from the
urinary tract have been investigated to overcome this.
These include elective voiding, catheterization, bladder
irrigation, and forced diuresis with intravenous frusem-
ide prior to delayed image acquisition [54-57].
Catheterization and irrigation prior to FDG-PET imaging
has a reported 40% false positive rate for detection of
recurrent or residual bladder cancer [57]. These measures
are invasive, making them less acceptable to patients, and
continuous bladder irrigation during image acquisition
increases staff exposure to radiation [58].
In those whom FDG-urine washout was encouraged
by diuretic injection, oral hydration and voiding, the
sensitivity and specificity for FDG-PET CT was 86.7%
and 100% respectively for detecting recurrent disease
within the bladder [56]. Further investigation is necessary
however to evaluate the impact of radiotherapy, endo-
scopic intervention and intravesical chemotherapy on
FDG-PET interpretation within the bladder. When
imaging is performed after chemotherapy the sensitivity
decreases to 50% and therefore 18-FDG PET results
should be interpreted with caution following systemic
treatment [59].
In a meta-analysis of the overall diagnostic accuracy of
18-FDG PET in bladder cancer, 6 studies involving 203
patients were assessed. The sensitivity and specificity of
18-FDG PET or PET/CT for staging or restaging
(metastatic lesions) of bladder cancer was 82% and
89% respectively. The global measure of accuracy was 0.92
[60]. The limitations accepted by the authors include
variation in the imaging technique used, one study used
PET alone which meant anatomical accuracy because of
the poor spatial resolution was lost, three studies were
retrospective in nature and only two studies assessed
detection of the primary tumor.
Although there is evidence that FDG PET-CT has a
diagnostic role for identifying metastatic bladder disease,in our clinical practice it is not used as principal staging
modality because of the limitations discussed above. In
certain circumstances, however, it provides important
contributory information when CT or MRI alone raises
uncertainty regarding staging.
Alternative radiotracers that are dependent on cell
proliferation, apoptosis, and angiogenesis, hypoxia and
growth factors are also under investigation [61,62].
11C-Choline and 11C-methionine are not excreted in the
urine and may have role in future imaging of bladder
cancer [24,54,63-65]. There is however limited data at
present to support routine clinical use.
Choline is an essential component of cell membranes.
Malignant tumors have a high turnover of cellular
membranes representing their increased proliferation
rate [66]. The normal bladder has low uptake with
11C-choline [63]. In the preoperative staging of 18 patients,
11C-choline was highly positive for primary and metastatic
bladder cancer. Uptake was seen in all primary transitional
cell carcinomas (mean SUV 7.3 ± 3.2 SD). In six patients,
11C-choline uptake was seen in lymph nodes as small as
5 mm; of those, four proceeded to surgery and three had
pathological conformation of nodal disease [64].
11C-Choline has also been used to detect residual
disease after TURBT. In a prospective study of 27
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comparable to CT alone for detecting residual cancer after
TURBT but appeared to be superior for detecting nodal
involvement, with reported sensitivity and specificity
of 62.5% and 100% versus 50% and 68.4% for
contrast-enhanced CT alone [65].
11C-Choline has a short half-life of approximately 20 -
minutes. Therefore clinical use is restricted predominantly
to those centers with an on-site cyclotron. 18 F-choline
analogs with greater half-lives have been developed to
overcome this; however, significant urinary excretion
occurs as compared to 11C-choline [67]. This represents aAnticipated clinical pathway for staging of confirmed muscle inv
Radiological work up**
In order to determine 
• Extent of local tumour invasion
• Nodal involvement
• Distant disease
CT chest, abdomen and pelvis
• Assessment of both local and distan
disease (>T3b)
+/-MRI pelvis
• Has some advantage for local stagin
over CT
+/-FDG-PET
• No evidence for routine use
+/-Bone scan
•No evidence for routine use
•considered when bone alkaline 
phosphataseis elevated or 
symptoms suggesting bone 
metastases  
Figure 2 Anticipated clinical pathway for staging of confirmed muscl
differ from imaging to determine extent of local and distant disease in con
Association of Urology guidelines 2012, available at http://www.uroweb.org
physician_gls/f_guidelines.asp#site.disadvantage for pelvic imaging as previously discussed
unless adequate urinary washout can be encouraged.
11C-Methionine is a radiolabeled amino acid and is a
potential tracer for visualizing protein metabolism, cellular
proliferation and amino acid transport. Compared to
18-FDG PET in identifying primary tumors within the
bladder, uptake is proportional to tumor stage, with a
reported sensitivity of 78% in tumors greater than 1 cm
but its value in local staging is not superior to conventional
imaging [54].
18 F Fluoride is a bone-seeking radiopharmaceutical
that accumulates at sites of increased bone formationasive bladder cancer*
t 
g 
Recommendation based on well 
conducted trials without  randomisation 
Recommendation based on well 
conducted trials without  randomisation 
Recommendation based on  meta-analysis  
of non randomised clinical  trials 
Recommendation made  in absence of 
directly applicable trials
e invasive bladder cancer. *Diagnostic investigations for haematuria
firmed muscle invasive bladder cancer. **Based on European
/guidelines/online-guidelines/ and http://www.nccn.org/professionals/
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metastases. It has been shown to have increased diagnos-
tic accuracy as compared to technetium-99 m-methylene
diphosphonate (99mTc-MDP) planar or single photon
emission computed tomography (SPECT) in other solid
tumors [68,69].
Non-FDG tracers are not in widespread clinical use
partly because of the lack of robust evidence supporting
clinical benefit but also because of their cost and limited
availability.
PET/CT: receptor specific radiopharmaceuticals
Imaging biomarkers using PET-CT and radioimmuno-
therapy opens the possibility of an individualized
therapeutic and imaging approach. The rationale is that a
tumor specific target is combined with a therapeutic
radioactive agent. The selective accumulation within the
target tissue can then be visualized on PET. These
imaging techniques have the potential to permit an ‘image
and treat approach’ by allowing tumor staging, estimation
of radiation dose distribution prior to therapy, and early
monitoring of treatment response [70].
Commonly used nuclides in other tumors types include
β emitters such as 131I and 90Y. They are attached to
somatostatin receptor binding agents such as 90Y-DOTA-
d-Phe(1)-Tyr(3)-octreotide (90Y-DOTATOC) for the
treatment of neuroendocrine tumors and to antibodies in
131I-tositumomab (BexxarW), 90Y-rituximab (ZevalinW) to
target the CD20 antigen on B cells for the treatment of
lymphoma [70,71].
Overexpression and amplification of epidermal growth
factor receptor (EGFR) (HER1 or ErdB1) and, or the HER2
gene is found in bladder cancers [72,73]. It therefore
represents a potential target for both molecular imaging
and therapy in those with known HER2-positive disease
[61]. Monoclonal antibodies for example, trastuzumab
labeled with 18 F, allows in vivo monitoring of HER2
expression by PET as well as assessing change in HER2
expression with therapy [74,75]. Trastuzumab has also
been labeled with nucleotides suitable for therapy with the
future possibility of treating metastatic disease and
improving the outcome of those with HER2 bladder
cancer [70,76,77].
PET/MRI
Image acquisition with PET/CT occurs sequentially
rather than simultaneously. This means there is loss of
temporal correlation, and additionally from the patient’s
perspective scanning time is significantly longer. The
possibility of assessing different functional parameters
using PET, DW MRI and combining that data with
high-resolution anatomical information from MRI may
provides new opportunities to study pathological and
biochemical processes in vivo [78-81].Most patients in the UK will present to urology teams
via a ‘one-stop hematuria clinic’, where a two-dimensional
US, urine cytology and flexible cystoscopy will be carried
out. On the basis of these results a TURBT will be
performed if appropriate. A CT scan will be undertaken
where there is evidence of MIBC, high-grade NMIBC or
suspicion of an upper tract lesion. However, in view
of the evidence supporting MRI (as discussed above)
our preferred practice is to stage local disease using
this modality. A summary of imaging modalities and their
current clinical role in staging known MIBC is presented
in Table 1 and Figure 2.
Patient perspectives
Image acquisition time and tolerability of any proposed
scan is important. CT image acquisition is usually within
minutes but some research MRI protocols may take
up to 1 h. This can impact on patient compliance
and predispose results to motion artifacts.
Use of MRI and US are free from ionizing radiation as
compared to CT and PET/CT. At our institution a 64-slice
multidetector CT scan of the chest, abdomen and pelvis is
associated with radiation exposure of 16 mSv during
imaging; PET/CT is associated with exposure of 14 mSv
(PET component 8 mSv; 6 mSv from a rapid image acqui-
sition CT). The clinical significance of these values in
terms of inducing second malignancy is small in the
context of the overall poor prognosis from muscle-
invasive and metastatic bladder cancer at present. MRI
scanning also does not require the use of iodine contrast
agents that can induce reactions potentially anaphylactic
in some individuals. In addition to allergy, intravenous
contrast is also omitted for CT scanning in the presence
of significant renal impairment.
Technology is rapidly changing so the ability to use this
information to identify the most effective intervention for
patients is critical. In the future we anticipate it will be
routine to tailor a patient’s treatment plan to both the
physiological and physical characteristics of their disease,
to monitor effectiveness of the intervention allowing a
more dynamic approach to treatment.
Conclusions
Accurate staging is important in determining prognostic
information and identifying appropriate treatment options.
CT and MRI remain central to bladder cancer staging.
The role of PET-CT using current tracers in staging and
guiding management of bladder cancer remains to be
defined. Future developments in functional imaging are
likely to be important in predicting treatment response
allowing timely identification of non-responders to guide
appropriate change in treatment but further studies are
required to determine which techniques or combination
of techniques will optimize patient care.
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